Description
DK
Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist
Reviewed June 2026
⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. Dosing is highly indication- and weight-specific; only your oncologist can determine the correct dose and tablet combination for you.
Is Lenvaxen 10 mg right for your situation?
Review these criteria with your oncologist before enquiring✔ You may be a candidate if
- ✓Radioactive iodine-refractory differentiated thyroid cancer (DTC), locally recurrent or metastatic
- ✓Advanced renal cell carcinoma (RCC), in combination with pembrolizumab or everolimus
- ✓Unresectable hepatocellular carcinoma (HCC), first-line
- ✓Advanced endometrial carcinoma, in combination with pembrolizumab
✖ May NOT be suitable if
- ✗Uncontrolled hypertension
- ✗Recent or active severe bleeding
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Recent surgery with unhealed wounds, or surgery planned within 4 weeks
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Lenvaxen 10 mg?
Lenvaxen 10 mg is a generic formulation of Lenvatinib — a multi-target tyrosine kinase inhibitor (TKI) — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each capsule contains 10 mg of lenvatinib, the same active molecule found in Lenvima® (Eisai/Merck), and is dispensed under the Named Patient Program.
Lenvatinib doses are built from combinations of capsule strengths (typically 4 mg and 10 mg) to reach the exact prescribed total — your oncologist will specify precisely which strengths and how many capsules to take together.
| Generic name | Lenvatinib (mesylate) |
| Reference brand | Lenvima® (Eisai / Merck) |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | Multi-target Tyrosine Kinase Inhibitor |
| Dosage form | Capsule — 10 mg |
| Pack size | 30 capsules per pack |
| Route | Oral · once daily, with or without food |
| Prescription | Required — oncologist only |
How Lenvatinib Works
Tumours rely on forming new blood vessels (angiogenesis) to grow and spread, and on several growth-signalling pathways to proliferate. Lenvatinib is a multi-target inhibitor that blocks several of these pathways simultaneously.
Lenvatinib inhibits VEGFR-1, -2, and -3 (blocking tumour blood vessel formation), along with FGFR1-4, PDGFR-alpha, RET, and KIT — a broader target profile than single-pathway TKIs. This dual anti-angiogenic and anti-proliferative action is why lenvatinib is active across multiple cancer types with different underlying biology. In the SELECT trial for thyroid cancer, lenvatinib demonstrated a median progression-free survival of 18.3 months versus 3.6 months for placebo. It received FDA approval for DTC in 2015, RCC (with everolimus) in 2016, and first-line HCC in August 2018.
Dosing by Indication
Lenvatinib dosing is indication-specific and, for HCC, weight-based. This is not a one-size dose — your oncologist will specify the exact regimen for your diagnosis.
| Differentiated thyroid cancer (DTC) | 24 mg once daily (monotherapy) |
| Renal cell carcinoma (RCC), first-line | 20 mg once daily + pembrolizumab 200 mg IV every 3 weeks |
| Renal cell carcinoma (RCC), with everolimus | 18 mg once daily + everolimus 5 mg once daily |
| Hepatocellular carcinoma (HCC), ≥60 kg | 12 mg once daily |
| Hepatocellular carcinoma (HCC), <60 kg | 8 mg once daily |
| Endometrial carcinoma | 20 mg once daily + pembrolizumab 200 mg IV every 3 weeks |
Doses are frequently reduced in steps (e.g. 24→20→14→10 mg for DTC) if side effects are not tolerable at the starting dose — this is common and expected, not a sign of treatment failure.
What to Expect: First 30 Days
- Before starting: Baseline blood pressure, thyroid function, liver function, and urine protein are checked. Blood pressure must be well-controlled before starting.
- Week 1: Hypertension is very common and often develops early — occurring in the majority of DTC patients on the 24 mg dose. Home blood pressure monitoring typically begins immediately.
- Weeks 2–4: Fatigue, diarrhoea, and decreased appetite commonly emerge. Hand-foot skin reactions may also appear. Your oncologist will assess tolerability and may adjust the dose.
Side Effects
Common · Usually Manageable
- Hypertension
- Fatigue
- Diarrhoea, nausea
- Decreased appetite / weight loss
- Hand-foot skin reaction
- Proteinuria
- Joint/muscle pain
Serious · Report Immediately
- Severe hypertension / hypertensive crisis
- Cardiac dysfunction (heart failure)
- Serious haemorrhage
- Arterial thromboembolic events (stroke, heart attack)
- Hepatotoxicity, GI perforation/fistula (rare)
- Posterior reversible encephalopathy syndrome (PRES) — rare
⚠ Call your doctor or go to A&E immediately if you experience:
- Severe headache, blood pressure reading dangerously high, chest pain, or vision changes
- Unusual bleeding that doesn’t stop, or blood in vomit/stool
- Sudden weakness, confusion, or difficulty speaking (possible stroke)
How to Take Lenvaxen 10 mg
- 1Once daily, same time each day — with or without food.
- 2Swallow capsules whole with water. Do not chew or crush.
- 3If unable to swallow capsules, an oral suspension method exists (dissolving in water or apple juice) but must follow the exact FDA-specified procedure and timing — ask your oncologist or pharmacist for the precise instructions rather than attempting this independently.
- 4Discontinue at least 6 days before any scheduled surgery, including dental procedures, due to wound-healing and bleeding risk. Confirm exact timing with your surgical team and oncologist.
- 5Storage: below 30°C, dry place, out of reach of children.
Frequently Asked Questions
Why does the dose depend on my body weight for liver cancer?
For hepatocellular carcinoma (HCC), lenvatinib dosing is weight-based — 12 mg daily for patients 60 kg or over, 8 mg daily for patients under 60 kg. This weight-based approach was established in the pivotal REFLECT trial to balance efficacy and tolerability. Your oncologist will confirm the correct dose based on your weight at treatment initiation.
Why do doses differ so much between cancer types?
Each indication was studied separately in its own clinical trials, which established different optimal dose-to-tolerability ratios for that specific cancer and treatment combination. Thyroid cancer uses monotherapy at 24 mg, while kidney and endometrial cancers combine lower lenvatinib doses with other targeted or immunotherapy drugs. Never apply one indication’s dose to another.
Is it normal for my dose to be reduced during treatment?
Yes. In clinical trials, the majority of patients on lenvatinib required at least one dose reduction due to side effects, most commonly hypertension. Dose reduction is a standard part of lenvatinib management, not a sign that the medicine has stopped working. Your oncologist follows a structured dose-reduction protocol based on the specific side effect and its severity.
Why is blood pressure monitoring so important?
Hypertension is the most common side effect of lenvatinib, occurring in the majority of thyroid cancer patients on the standard dose. Since lenvatinib works partly by blocking blood vessel growth signalling (VEGFR), it commonly raises blood pressure. Regular home monitoring allows early detection and management before it becomes dangerous.
How do I order Lenvaxen through Meds For Cancer?
Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription specifying your diagnosis, weight (if HCC), and exact capsule strengths/quantities required. Our team will verify the prescription, confirm availability and pricing for your country, and arrange secure international shipping under the Named Patient Program.
🛡 Named Patient Program — Regulatory Framework
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable. This service does not constitute retail pharmacy dispensing.
Clinical References
- Schlumberger M, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT). NEJM 2015;372:621–630.
- Motzer RJ, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. NEJM 2021;384:1289–1300.
- Kudo M, et al. Lenvatinib versus sorafenib in first-line hepatocellular carcinoma (REFLECT). Lancet 2018;391:1163–1173.
- FDA Prescribing Information: Lenvima (lenvatinib). Eisai, 2023.
Reviews
There are no reviews yet.